|ID:693 ||Gabapentin||Search Links: General Info : Protocols : Patient Info|
|Description||This test is no longer routinely available. Please contact the Duty Biochemist for further discussion if required Anticonvulsant drug.|
|Indication||Therapeutic drug monitoring (TDM) . To assess compliance or suspected toxicity. TDM should be applied when modifying treatment in any way or to establish baseline values during successful treatment.|
|Additional Info||Following absorption gabapentin is cleared entirely unchanged by the kidneys with a plasma elimination half-life of 5-6 hrs and the drug is not protein bound. Adverse drug reactions are mainly CNS related and associated with elevated drug concentrations in plasma/serum. A reasonable correlation has been demonstrated between plasma/serum levels and seizure control.
|Interpretation||The drug is absorbed from the proximal small bowel into the blood stream by the L-amino acid transport system with bioavailability of gabapentin reported to be dose-dependent|
|Ref. Range (Male)|| |
|Ref. Range (Female)|| |
|Ref. Range (Paed)|| |
|Ref. Range Notes|| 43862|
|IP Acute TAT||- Contact Laboratory|
|IP Routine TAT||At least 1 week|
|GP Acute TAT||- Contact Laboratory|
|GP Routine TAT||1 week|
|Turnround Comment||Dr Alun Hutchings:HutchingsAD@cardiff.ac.uk|
Originally edited by : . Last edited on 23/11/2018 16:45:29. Published By on 23/11/2017 16:45:29.